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The Global Health Innovative Technology (GHIT) Fund: 
ﬁ nancing medical innovations for neglected populations
The newly launched Global Health Innovative 
Technology (GHIT) Fund, which is multisectoral, 
interdisciplinary, and not for proﬁ t, aims to expedite 
the generation of novel medical technologies 
and drugs to diagnose, prevent, and treat high-
prevalence infectious diseases worldwide. The GHIT 
Fund represents the ﬁ rst public–private partnership 
to involve a national government, a UN agency, a 
consortium of pharmaceutical companies, and an 
international philanthropic foundation (founding 
partners are the Japanese Ministry of Foreign Aﬀ airs; 
the Japanese Ministry of Health, Labour and Welfare; 
the UN Development Programme; Astellas Pharma; 
Daiichi Sankyo Company; Eisai Company; Shionogi 
& Company; Takeda; and the Bill & Melinda Gates 
Foundation). The initial targets are key poverty-
exacerbating diseases prevalent in developing 
nations—namely, HIV/AIDS, malaria, tuberculosis, 
and 17 disorders designated as neglected tropical 
diseases by WHO (panel). These disorders still thrive in 
poor, marginalised communities, causing severe pain, 
disability, and death for more than 1 billion people. 
Investments to control them can substantially reduce 
poverty,1 but overall funding for neglected tropical 
diseases has remained static since 2009.2
The Tokyo-based Fund is a result of recent changes in 
Japan’s research and development system, placement of 
global health as a central component of foreign policy, 
and the country’s proactive pharmaceutical sector, 
together with a shift in focus of international eﬀ orts 
since the mid-1990s to combat neglected tropical 
diseases. With a broad-based participatory approach, 
Japan aims to maintain its role at the forefront of global 
public health initiatives, and to prioritise the health aid 
sector.3,4 The GHIT Fund will draw on Japan’s advanced 
technology and innovation sectors to accelerate the 
creation of new biomedical systems, methods, and 
products that are appropriate, eﬀ ective, aﬀ ordable, 
and easy-to-use. Where possible, capacity building and 
technology-transfer components will be integrated 
into these eﬀ orts. The Fund’s main goal will be the 
generation of novel drugs, vaccines (both preventive 
and therapeutic), and diagnostic technologies.
The Fund will enable international partnerships in 
research and development, involving existing or new 
Japanese and non-Japanese entities. Its work might 
include anything from discovery through to licensing. 
The ﬁ rst requests for proposals issued by the Fund 
included: preclinical drug development (eg, in-vitro 
and in-vivo studies, chemistry, and formulation); 
clinical development (eg, phase 1 to phase 3 clinical 
trials, and manufacturing); and licensing (eg, WHO 
prequaliﬁ cation).
In addition to its grant-making mechanism, the Fund 
will invest in a new drug-discovery screening platform 
to assist the screening of compound libraries housed 
within Japanese companies and academic institutions. 
Japanese entities will provide compounds to partners, 
with the Fund reimbursing screening costs and 
leveraging screening programmes of existing product-
development partners (eg, the Drugs for Neglected 
Diseases initiative, the Global Alliance for TB Drug 
Development, and the Medicines for Malaria Venture).
In 2012, research-based pharmaceutical companies 
were engaged in 132 projects to develop new medicines 
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Panel: Initial target diseases
• HIV/AIDS
• Malaria
• Tuberculosis
• Buruli ulcer
• Chagas disease (American trypanosomiasis)
• Dengue
• Dracunculiasis (guinea worm)
• Echinococcosis
• Foodborne trematodiasis
• Human African trypanosomiasis (sleeping sickness)
• Leishmaniasis
• Leprosy
• Lymphatic ﬁ lariasis (elephantiasis)
• Onchocerciasis (river blindness)
• Rabies
• Schistosomiasis (bilharziasis)
• Soil-transmitted helminthiases (ascariasis [roundworm], 
trichuriasis [hookworm], and ancylostomiasis 
[whipworm])
• Trachoma
• Taeniasis and cysticercosis
• Endemic treponematoses (yaws, endemic syphilis, pinta)
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and vaccines for global health, whereas almost all 
the important, innovative vaccines introduced in 
the past century originated in public-sector research 
institutions.5 In view of this fact, the Fund’s founding-
partner pharmaceutical companies, along with national 
research institutions and universities, will allow 
improved access to some of the world’s richest and most 
diverse chemical collections. 
With an initial committed capital of more than 
US$100 million, the Fund will follow an evidence-
based operational system, allocating grants to 
encourage international research collaborations to 
share and exploit expertise, knowledge, technologies, 
and resources. An independent selection committee 
of experts will review and select grant proposals for 
approval by the board of directors. A transparent 
operational policy will ensure data quality, security, 
and open access, with a view to perfecting translation 
into optimum end products. Conﬁ dentiality will be 
respected, in addition to all intellectual and proprietary 
rights. The Fund will encourage the equitable sharing of 
information and knowledge, and assignation of rights 
or licences to third parties.
End-products emerging from GHIT-supported 
endeavours will be regarded as public health goods, and 
their accessibility to individuals who need them most 
will be paramount, meaning that they will be priced 
on a no gain, no loss basis. Products mainly funded by 
the GHIT Fund will be subject to royalty-free licences 
in countries included on the World Bank’s list of low-
income countries, whereas countries on the Bank’s 
lower-middle-income and upper-middle-income listings 
will beneﬁ t from licences designed to improve access for 
poor patients and populations.
WHO recognised the serious lack of biomedical 
innovation and access to medical devices, particularly 
for developing countries, more than two decades ago. 
The need for concerted action to create a framework 
for research and development that coordinates and 
ﬁ nances medical innovations for neglected populations 
was re-emphasised by the Commission on Intellectual 
Property Rights, Innovation and Public Health in 2006,6 
since when little has happened. The GHIT Fund is Japan’s 
attempt to rectify that wholly unacceptable inaction.
*B T Slingsby, Kiyoshi Kurokawa
Global Health Innovative Technology (GHIT) Fund, Tokyo 
106-0032, Japan (BTS); and National Graduate Institute for Policy 
Studies (GRIPS), Tokyo, Japan (KK)
info@ghitfund.org
We declare that we have no conﬂ icts of interest. We thank GHIT Fund staﬀ  and 
Andy Crump for their invaluable assistance in the preparation of this Comment.
1 Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion 
through control of neglected tropical diseases. Lancet 2009; 373: 1570–75.
2 Moran M, Guzman J, Henderson K, et al. Global Funding of Innovation for 
Neglected Diseases (G-Finder). Neglected disease research and 
development: a ﬁ ve year review. Policy Cures, 2012. http://www.
policycures.org/downloads/GF2012_Report.pdf (accessed May 1, 2013).
3 Japanese Organization for International Cooperation in Family Planning 
(JOICFP), Health and Development Service (HANDS). A study on Japan’s 
global health aid policy: toward the formulation of a new policy. Final 
report, March, 2010. www.mofa.go.jp/policy/oda/sector/health/pdfs/
study.pdf (accessed May 1, 2013).
4 Sugiyama H, Yamaguchi A, Murakami H. Japan’s global health policy: 
developing a comprehensive approach in a period of economic stress. A 
report of the Global Health Policy Center and the HGPI Global Health Policy 
Center. Washington, DC: Center for Strategic and International Studies, 
2013. http://csis.org/ﬁ les/publication/130506_Sugiyama_
JapanGlobalHealth_web.pdf (accessed May 1, 2013).
5  Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. 
The role of public-sector research in the discovery of drugs and vaccines. 
N Engl J Med 2011; 364: 535–41.
6 WHO. Public health, innovation and intellectual property rights: report of 
the Commission on Intellectual Property Rights, Innovation and Public 
Health. http://apps.who.int/medicinedocs/documents/s14146e/s14146e.
pdf (accessed May 1, 2013).
